Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;60(4):519-528.
doi: 10.1038/s41409-025-02524-2. Epub 2025 Feb 12.

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

Jakob R Passweg  1 , Helen Baldomero  2 , Marina Atlija  3 , Iliana Kleovoulou  3 , Aleksandra Witaszek  3 , Tobias Alexander  4 , Emanuele Angelucci  5 , Dina Averbuch  6 , Ali Bazarbachi  7 , Fabio Ciceri  8 , Raffaella Greco  8 , Mette D Hazenberg  9   10 , Krzysztof Kalwak  11 , Donal P McLornan  12 , Bénédicte Neven  13 , Zinaida Perić  14 , Antonio M Risitano  15 , Annalisa Ruggeri  8 , Isabel Sánchez-Ortega  16 , John A Snowden  17 , Anna Sureda  18
Affiliations

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

Jakob R Passweg et al. Bone Marrow Transplant. 2025 Apr.

Abstract

In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52.5%), in allogeneic HCT (+7.8%) but none in autologous HCT (+0.4%). Main indications for allogeneic HCT were myeloid (11,748; 60.7%), lymphoid malignancies (4,850; 25.0%), and non-malignant disorders (2558; 13.2%). Use of allogeneic HCT increased for AML (+12.1%) and for NHL (+11.0%), particularly in T-NHL (+25.6%). Main indications for autologous HCT were lymphomas (7890; 32.2%), PCD (14,271; 58.2%), and solid tumors (1608; 6.6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1.0%, haploidentical donors by +11.7%, and unrelated donors by +11.1%. Cord blood HCT decreased again by -5.4%. Pediatric HCT activity increased slightly (5455; +0.1%) with differences between allogeneic (4111; -0.5%) and autologous HCT (1344: +1.7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases. Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JAS declares advisory boards for Jazz, Medac, and Vertex. There are no other conflicts of interest to declare. The writing of the manuscript was the sole responsibility of the authors. Ethics approval and consent to participate: This manuscript follows the relevant guidelines and regulations as appropriate. All graphics were self-generated. The data analysis is based on center-level data and no individual patient data are included, as such no ethics committee approval is needed. Patient informed consent is not needed.

Figures

Fig. 1
Fig. 1
Number of patients receiving the first allogeneic or autologous HCT from 1990 to 2023.
Fig. 2
Fig. 2. Change in main disease indication for allogeneic and autologous HCT 1990 to 2023.
a Allogeneic HCT. b Autologous HCT.
Fig. 3
Fig. 3. Major trends in disease indication and type of donor for allogeneic HCT from 1990 to 2023.
a Allogeneic HCT for AML in early stage, late stage, and secondary AML from 1990 to 2023. b Change in type of donor in AML (all stages) from 1990 to 2023. c Allogeneic HCT for MDS or MDS/MPN overlap and MPN from 2004 to 2023. d Allogeneic HCT for CML in early and late stages from 1990 to 2023.
Fig. 4
Fig. 4
Change in type of donor for first allogeneic HCT from 1990 to 2023.
Fig. 5
Fig. 5
Increase in the number of patients receiving CAR-T therapy by main indication from 2019 to 2023.
See this image and copyright information in PMC

References

    1. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transpl. 1991;8:197–201. - PubMed
    1. Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472. - PubMed
    1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217–39. - PMC - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. - PMC - PubMed